SV Health Investors β Full Portfolio
214 tracked investments Β· page 1 of 2 Β· listed companies and verified rows first
Co-investorsOne Equity Partners
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsForesite CapitalMission Bay CapitalMission BiocapitalMRL Ventures FundPolaris Partners
Enabling telemedicine and digital health
HealthtechBoston, US
Ido Schoenberg(Executive Officer, Director)inRoy Schoenberg(Executive Officer, Director)inJames Malone(Executive Officer)inBradford F. Gay(Executive Officer)
Co-investorsHanaco Venture CapitalMartin Ventures
Insulet develops the Omnipod, a tubeless, wearable, disposable insulin delivery Pod, along with automated insulin delivery systems for people managing insulin-dependent diabetes.
Digital HealthHardwareHealthtechMedical DevicesActon, US
Co-investorsWinklevoss Capital
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+4 more
SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.
AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US
Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in
Board seatPaul LaVioletteΒ· per SEC Form D
Co-investorsLumira VenturesS3 VenturesDeerfield Management CompanyJohnson & Johnson Innovation β JJDC
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsDCVC BioRA CapitalDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.DCVC (Data Collective)
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
PartnerCharles DunnΒ· led
Co-investorsAccess BiotechnologyCanaan PartnersSanofi VenturesSR One Capital ManagementBritish Business BankJanus Henderson Investors
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)Greg Lazar(Co-Founder & Chief Scientific Officer)Richard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)
BoardAlicia Levey(Director)Michael Ross(Director)
Co-investorsQiming Venture PartnersVersant VenturesAlexandriaDementia Discovery FundQiming HealthcareQiming Venture Partners USA
EBT Medical develops neuromodulation technologies targeting the Saphenous nerve to treat pelvic health disorders, particularly overactive bladder.
BiotechMedical Devices
Paul Yoo(Co-founder, President & Chief Scientific Officer)Sasha John(Co-founder and Chief Innovation Officer)inKeith R Carlton(Chief Executive Officer)
Co-investorsGenesys CapitalToronto Innovation Acceleration Partners
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.
BiotechHealthtech
Jan Thirkettle(CEO Director)
Co-investorsEpidarex CapitalOno Venture Investment, Inc.Dementia Discovery Fund
Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.
AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB
Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)Soumya Raychaudhuri(Founder)David A. Tuveson(Founder)Susan Hill(Chief Executive Officer)
Co-investorsForbionGV (Google Ventures)Northpond Ventures
Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.
AI & Machine LearningBiotechHealthtech
Susan Hill(Founder & Chief Executive Officer)Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)Soumya Raychaudhuri(Founder)David A. Tuveson(Founder)
Co-investorsGV (Google Ventures)ForbionJohnson & Johnson Innovation β JJDCNorthpond Ventures
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsCriteria Bio VenturesNovartis Venture FundBritish Business BankM VenturesDementia Discovery Fund
Packaging Compliance Labs is an industry leader providing sterile packaging solutions, design validation, and contract packaging services for medical device and life sciences manufacturers.
Advanced ManufacturingEnterprise SoftwareMedical DevicesSaaSGrand Rapids, US
Matthew Lapham(CEO & Co-Founder)Matt Lapham(CEO)
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsLongwood FundOxford Science EnterprisesSofinnova Partners
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
BoardOlga Danilchanka(Director)Laia Crespo-Martin(Director)
Co-investorsMRL Ventures FundSanofi VenturesAngelini VenturesMitsui Global InvestmentApollo Health VenturesDementia Discovery Fund+1 more
Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).
HealthtechMedical DevicesNew York, US
Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)
Board seatPaul LaVioletteΒ· per SEC Form D Β· $2M raise Β· filed Apr 2016
Co-investorsDeerfield Management Company
CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control.
BiotechHealthtechMedical DevicesMarlborough, US
Lauren Jennings(Executive Officer)Warren Clark(Executive Officer)Stephen Sagon(Executive Officer, Director)Anjie Roldan(Executive Officer)inWarren R. Clark III(Executive Officer)Stephen W. Sagon(Executive Officer, Director)
Board seatPaul LaVioletteΒ· per SEC Form D
Co-investorsBioBrit
Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.
BiotechTewksbury, US
George J. Fazio(Executive Officer, Director)Dan B. Curtis(Executive Officer)
BoardKevin Gillis(Director)inGerald Brunk(Director)inIrit Yaniv(Director)
Board seatPaul LaVioletteΒ· per SEC Form D Β· $11.1M raise Β· filed Jun 2025
Co-investorsAccelmed PartnersGeneral CatalystLumira VenturesThird Rock Ventures
RejuvenAir, developed by CSA Medical, is a bronchoscopic cryosurgical device that sprays metered doses of liquid nitrogen to destroy damaged airway cells and treat the underlying cause of COPD with Chronic Bronchitis.
HealthtechMedical DevicesLutherville, US
Ellen Sheets(Executive Officer, Director)inIan J. Vawter(Executive Officer)Steven Schaefer(Executive Officer)William Floyd(Executive Officer, Director)inVincent Owens(Director)Richard Kent(Director)
Board seatPaul LaVioletteΒ· per SEC Form D
Co-investorsAscension VenturesFirst Analysis
HealthtechSanta Rosa, US
Dan Rose(Executive Officer)Gordon Bishop(Executive Officer, Director)David Boyle(Executive Officer)Dan T. Lemaitre(Executive Officer, Director)Chris Richardson(Executive Officer)
BoardYuval Binur(Director)
Board seatPaul LaVioletteΒ· per SEC Form D
Co-investorsFOUNDATION MEDICAL PARTNERSNew Leaf Venture Partners
Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.
Digital HealthHealthtechMedical DevicesWoodridge, US
Harry Rowland(Executive Officer, Director)Anthony I Nunez(Executive Officer, Director)Anthony A. Nunez(Executive Officer, Director)Anthony Nunez(Founder)in
BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)
Board seatPaul LaVioletteΒ· per SEC Form D
Co-investorsBioventures InvestorsJumpstart VenturesLumira VenturesOSF VenturesSeroba Life Sciences
Lunair Medical develops an implantable closed-loop system that senses respiration and stimulates the phrenic nerve to treat moderate-to-severe sleep apnea, avoiding masks, mouthpieces, and wearables.
Digital HealthHealthtechMedical DevicesMinneapolis, US
Mark Christopherson(Executive Officer, Director)inHoward Levin(Director)
BoardDavid Neustaedter(Director)Michael Hurley(Director)
Board seatPaul LaVioletteΒ· per SEC Form D
Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions.
BiotechDigital HealthHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Director)Kevin Hanley(Executive Officer)Michael Goldstein(Executive Officer)Daniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)Donald Notman(Executive Officer)
Board seatCharles WardenΒ· per SEC Form D
Co-investorsAscension VenturesSofinnova VenturesTop Corner CapitalAgent Capital
HealthtechSan Diego, US
Martyn Gross(Executive Officer, Director)Kathy Scott(Executive Officer)
BoardJohn Buhler(Director)Rex Bright(Director)David Hale(Director)
Board seatPaul LaVioletteΒ· per SEC Form D Β· $43M raise Β· filed Oct 2021
Co-investors7wire Ventures
BiotechHealthtechPompano Beach, US
Laura Tyler Perryman(Director)Laura T Perryman(Executive Officer, Director)Regina Groves(Executive Officer, Director)Virginia Sullivan(Executive Officer)Marc Loev(Director)Richard Chen Mao(Director)
Board seatPaul LaVioletteΒ· per SEC Form D Β· $8M raise Β· filed Sep 2020
Co-investorsEmergent Medical Partners, LLP
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)Todd M Pope(Executive Officer, Director)Joseph P Slattery(Executive Officer)Todd M. Pope(Executive Officer, Director)James J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)
Board seatPaul LaVioletteΒ· per SEC Form D
Co-investorsAisling CapitalQuaker BioVenturesSV Life Sciences
BiotechMaple Grove, US
JON PATRICK ST. GERMAIN(Executive Officer)DAVID KRENN(Executive Officer)JOHANN NEISZ(Executive Officer, Director)
BoardMARY LINCOLN CAMPBELL(Director)MITCHELL DANN(Director)PAUL A. LAVIOLETTE(Director)in
Board seatPaul LaVioletteΒ· per SEC Form D
Co-investorsKaiser Permanente Ventures
Co-investorsMPM BioImpactNovartis Venture FundUCL Technology Fund
Co-investorsPappas Capital
Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.
AI & Machine LearningBiotechDeep TechVermont, US
Co-investorsGrandBanks CapitalLaunchCapitalLux CapitalPremji InvestMithril Capital ManagementOrbiMed+1 more
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomTenmileAbingworthAlly Bridge Group+2 more
Co-investorsRA Capital
HealthtechCalabasas, US
Nitin Nanda, M.D.(Executive Officer, Director)Nitin Nanda(Executive Officer, Director)
BoardMichael Balmuth(Became Director as of July 8, 2016)inJohn Eugene Hill(Became Director as of July 8, 2016)Deepak Chopra(Director)Vikram Marla(Resigned as director July 8, 2016)
Ally Bridge Group is a healthcare investment management firm investing across the global life sciences industry through complementary private equity and public equity strategies.
BiotechHealthtechMedical DevicesNew York, US
Frank Yu(Founder, Chief Executive Officer, Chief Investment Officer)in
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMAβ’), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.
BiotechHealthtechMedical DevicesChanhassen, US
Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)
BoardKlaus Veitinger(Director)inImran Eba(Executive Officer)in
Co-investorsOrbiMedHealthQuest CapitalSamsara BioCapitalAction Potential Venture Capital Ltd.
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.
BiotechCambridge, GB
Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)
Co-investorsAdvent Life SciencesNovartis Venture FundDementia Discovery FundEuropean Investment FundForbionGilde Healthcare+1 more
AqueSys was a clinical-stage ophthalmic device company behind the XEN Gel/XEN45 glaucoma shunt, acquired by Allergan in 2015.
Co-investorsRho Capital PartnersRho Ventures
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersM VenturesNovartis Venture FundPfizer Venture InvestmentsRA CapitalSofinnova Partners
Co-investorsPfizer Venture Investments
Advanced ManufacturingBiotechHardwareLebanon, US
Tillman Gerngross(Director)Errik Anderson(Director)Warren Kett(Executive Officer)Jon Sheller(Executive Officer)Jonathan Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)
Co-investorsOrbiMedMithril Capital ManagementSands Capital VenturesSV Life Sciences
AVROBIO develops ex vivo lentiviral vector-based hematopoietic stem cell gene therapies to treat lysosomal disorders by permanently integrating therapeutic genes into patient stem cells manufactured outside the body.
BiotechDigital HealthHealthtechMedical Devices
BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.
Digital HealthHealthtechMedical DevicesSeattle, US
Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)
Co-investorsAPERTURE Venture PartnersAphelion CapitalAscension VenturesLumira VenturesRC CapitalRex Health Ventures+1 more
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)KEVIN LEE(Executive Officer, Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalLongwood FundSR One Capital ManagementVertex Ventures HC
Biotechnology company developing drugs to treat aging and associated diseases
Co-investorsFelicis VenturesOUP (Osage University Partners)
Brixton Bio develops Reneurx therapy, a treatment aimed at providing long-lasting pain relief for up to six months from a single administration.
BiotechMedical Devices
Charles Sidoti(Founder)in
Co-investorsAngel Physicians FundExcelestar VenturesFemHealth VenturesSchooner Capital
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsEisai Innovation, Inc.MRL Ventures Fund
HealthtechMenlo Park, US
Brett Hale(Executive Officer)Maria Sainz(Executive Officer, Director)
BoardLou Bock(Director)Jeani Delagardelle(Director)Casey Tansey(Director)Rodney Ferguson(Director)
Co-investorsArcher Capital GroupArcher Venture CapitalNew Leaf Venture PartnersSV Life Sciences
Celerion is a contract research organization specializing in early phase clinical drug development, providing bioanalytical services and laboratory testing that generate clinical data for pharmaceutical clients.
BiotechDigital HealthHealthtechMedical DevicesLincoln, US
Co-investorsH.I.G. CapitalH.I.G. HealthBridge Partners
Scottsdale, US
Michelle Miller(Executive Officer)Adam T. Miller(Executive Officer, Director)Michael McNelis(Executive Officer)Glenn M. Parker(Executive Officer, Director)
BoardJames J. Quagliaroli(Member of the Management Board of Issuer)in
Co-investorsSilversmith Capital Partners
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)Ottavio V. Vitolo(Chief Medical Officer)
Co-investorsForesite CapitalGV (Google Ventures)Dementia Discovery FundSV Life SciencesDementia DiscoveryLightstone Ventures+2 more
Co-investorsAscension VenturesHLM Venture Partners
EMED makes infusion pump systems and subcutaneous delivery devices for patients requiring immunoglobulin therapy and other biologics.
Digital HealthHardwareHealthtechMedical Devices
Phil Parvin MBAin
Co-investorsAdvent Life SciencesEssex Woodlands Healthcare Partners
BiotechCambridge, US
Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)
BoardNoubar B. Afeyan, Ph.D.(Director)
Co-investorsFlagship PioneeringKaiser Permanente Ventures
Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.
BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US
Christine Lemke(Executive Officer, Director)Deborah Kilpatrick(Executive Officer, Director)Leslie Oley Wilberforcein
BoardDavid Fleshman(Director)Rowan Chapman(Director)
Co-investorsAsset Management CompanyB Capital GroupB4 CapitalCross Creek AdvisorsFresco CapitalG Squared+4 more
Global company developing next-generation eye disease therapies; acquired by Merck & Co.
Co-investorsBain Capital Life SciencesJeito CapitalMRL Ventures Fund
Co-investorsNew Enterprise Associates (NEA)
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)Albert M. Kim(Chief Medical Officer)
Co-investorsAN Venture PartnersRA CapitalSanofi VenturesCatalio Capital Management
BiotechBoston, US
Pavan Cheruvu(Director)Alvin Shih(Executive Officer, Director)Komal Joshi(Executive Officer)Pieter Boelhouwer(Director)David-Alexandre C. Gros(Executive Officer, Director)
BoardCharles Dunn(Director)
Co-investorsCatalio Capital ManagementRA Capital
Fort Worth, US
Stacie Bratcher(Executive Officer)Jim Douthitt(Mr. Douthitt is the Secretary of the Issuer.)
BoardJames Glynn(Director)Thomas Flynn(Director)inStephen Griggs(Director)Liston Thomas(Director)
Co-investorsFrazier Life SciencesLongwood Fund
Clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics for central nervous system disorders.
Leica Microsystems manufactures optical microscopy instruments and fluorescence reagents for scientific research and diagnostics.
BiotechDeep TechHardwareHealthtechMedical DevicesWetzlar, DE
Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use.
BiotechHealthtechMedical DevicesDenver, US
Co-investorsCorewell Health VenturesEscalate Capital PartnersFrazier Healthcare PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersKaiser Permanente Ventures+2 more
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.
BiotechDeep TechCambridge, GB
David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in
Co-investorsNovartis Venture FundDementia Discovery FundForbion
Miach Orthopaedics develops implants that help the body restore its own connective tissue, with an initial focus on treating ACL tears.
HealthtechMedical DevicesWestborough, US
Martha Murray(Founder)inChris Joyce(Executive Officer)inPatrick McBrayer(Executive Officer, Director)inSean Sansiveri(Director)Pieter Wolters(Director)
BoardMarc-Andre Marcotte(Director)
Co-investorsAmzak HealthAPERTURE Venture PartnersEndeavour Vision
BiotechHealthtechIndianapolis, US
Richard Dodson(Executive Officer, Director)James Floyd(Executive Officer, Director)Anders Weaver(Executive Officer, Director)Phillip Clem(Executive Officer, Director)
Co-investors1315 CapitalSofinnova Ventures
HealthtechNewark, US
John Hendrick(Executive Officer, Director)Tim Dumke(Executive Officer)
BoardStephen Martin(Director)William Link(Director)Ryan Schwarz(Director)Steven Waite(Director)
Co-investorsMPM BioImpactOxford Finance LLCSV Life SciencesVersant Ventures
Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Co-investorsAccess BiotechnologyBain Capital Life SciencesLightstone VenturesPfizer Venture InvestmentsRA Capital
Nira Medical consolidates independent neurology practices across the United States to improve patient access to neurological care.
Digital HealthHealthtechMedical Devices
Co-investorsSilversmith Capital PartnersTRANSFORMATION CAPITAL
BiotechJackson, US
Irene Griswold-Prenner(Executive Officer, Director)
BoardZach Hall(Director)Ephraim Heller(Director)William McDowell(Director)Regis Kelly(Director)
Co-investorsDementia Discovery FundSofinnova Partners
Nuwellis develops medical technology solutions for managing fluid overload in patients with cardiorenal conditions, serving clinicians and healthcare providers in inpatient and outpatient settings.
BiotechHardwareHealthtechMedical DevicesEden Prairie, US
Neil P. Ayotte(Executive Officer)Rob Scott(Executive Officer)Nestor Jaramillo, Jr.(Executive Officer, Director)Brian Brown(Executive Officer)David A. Rosa(Executive Officer, Director)Claudia Drayton(Executive Officer)
Co-investorsAscension VenturesKaiser Permanente Ventures
Co-investorsAndera Partners
Onkos Surgical develops limb salvage and orthopedic reconstruction implants and systems for treating musculoskeletal cancer and complex orthopedic conditions.
HardwareHealthtechMedical DevicesParsippany, US
Patrick Treacy(Founder)inAntony Koblish(Director, Promoter)inBrad Tyler(Executive Officer)in
BoardAdele Oliva(Director)Stephen Bloch(Director)Paul Touhey(Director)
Co-investors1315 CapitalCanaan PartnersJSD Capital, LLC
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesClarusSV Life Sciences
Perfuze develops medical devices for the treatment of acute ischemic stroke, focused on addressing unmet clinical needs in mechanical thrombectomy.
Deep TechHealthtechMedical DevicesGalway City, IE
Wayne Allen(Co-Founder, CEO, Director)inLiam Mullins(CTO and Co-founder)in
Co-investorsSeroba Life Sciences
Pivot Point Consulting provides managed IT services, EHR consulting, strategic advisory, analytics and AI solutions, and ERP implementation services to healthcare organizations.
AI & Machine LearningEnterprise SoftwareHealthtechSaaS
Podimetrics offers a remote monitoring and care program for people with complex diabetes, centered on the SmartMat device that collects foot-health data to enable early intervention and prevent complications such as amputations.
Digital HealthHealthtechMedical DevicesSomerville, US
David Linders(Executive Officer, Director)inJonathan Bloom(Executive Officer, Director)
BoardAaron Sandoski(Director)in
Co-investorsNorwich VenturesScientific Health DevelopmentPolaris PartnersRock Health
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalLongwood FundSR One Capital ManagementVivo Capital+2 more
Clinical stage company transforming lives in immune mediated disease
Co-investorsAlbionVCJeito Capital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesAmgen Ventures+6 more
Ria Health provides telemedicine-based treatment for alcohol and opioid use disorders, delivered by a team of physicians, nurse practitioners, and counselors.
Digital HealthHealthtechMental HealthWellness & FitnessSan Francisco, US
Bill Stapleton(CEO)
Co-investorsSOSV
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
BoardMike Dial(Director)in
Co-investorsIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalDementia Discovery FundHatteras Venture Partners+1 more
Co-investorsProspect Venture Partners
Rondo Therapeutics develops immune-engaging bispecific antibodies designed to treat solid tumors with tuned immune-activating arms and tumor-localized activity to reduce side effects.
BiotechHealthtech
Shelley Force Aldred(Chief Executive Officer & Co-Founder)Nathan Trinklein(Chief Scientific Officer & Co-Founder)
Schweiger Dermatology Group is a dermatology practice that provides medical and cosmetic dermatological services to patients, with locations across multiple areas and handling insurance billing, co-pays, and cosmetic procedures.
Digital HealthHealthtechMedical DevicesWellness & FitnessNew York, US
Dr. Eric Schweiger
Co-investorsHLM Venture Partners
HealthtechSunnyvale, US
Thomas Afzal(Executive Officer, Director)
BoardPeter van der Velden(Director)David Milne(Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)
Co-investorsHLM Venture PartnersLumira VenturesSV Life Sciences
Spineology develops minimally invasive spine surgery implants, including its flagship OptiMesh interbody fusion technology that delivers a bone graft-containing implant through a small surgical portal.
BiotechHardwareHealthtechMedical DevicesSt. Paul, US
Stephen D. Kuslich(Founder)JAMISON YOUNG(Executive Officer)inBRIAN SNIDER(Executive Officer, Director)inBrian Snider(Chief Executive Officer & Board Member)inSteve Nemitz(Chief Financial Officer)inAmanda Bloom(Executive Vice President, Marketing)in
Co-investors1315 CapitalRC Capital
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)Scott Byrd(Executive Officer, Director)
Co-investorsFrazier Life SciencesMonograph Capital PartnersSanofi VenturesDementia Discovery FundTPG
SUN Behavioral Health operates inpatient hospitals and home- and community-based programs providing mental health and substance use disorder treatment across a full continuum of care, from crisis stabilization to long-term recovery.
Digital HealthHealthtechMental Health
Steve Page(CEO & Founder)in
BoardEugene Hill(Director)Wilfred Jaeger(Director)David Fitzgerald(Director)Brian Murphy(Director)
Co-investorsLLR
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.